Literature DB >> 25241192

CD4 aptamer-RORγt shRNA chimera inhibits IL-17 synthesis by human CD4(+) T cells.

Pingfang Song1, Yuan K Chou1, Xiaowei Zhang1, Roberto Meza-Romero2, Kentaro Yomogida3, Gil Benedek2, Cong-Qiu Chu4.   

Abstract

Cell type specific delivery of RNAi to T cells has remained to be a challenge. Here we describe an aptamer mediated delivery of shRNA to CD4(+) T cells targeting RORγt to suppress Th17 cells. A cDNA encoding CD4 aptamer and RORγt shRNA was constructed and the chimeric CD4 aptamer-RORγt shRNA (CD4-AshR-RORγt) was generated using in vitro T7 RNA transcription. 2'-F-dCTP and 2'-F-dUTP were incorporated into CD4-AshR-RORγt for RNase resistance. CD4-AshR-RORγt was specifically uptaken by CD4(+) Karpas 299 cells and primary human CD4(+) T cells. The RORγt shRNA moiety of CD4-AshR-RORγt chimera was cleaved and released by Dicer. Furthermore, CD4-AshR-RORγt suppressed RORγt gene expression in Karpas 299 cells and CD4(+) T cells and consequently inhibited Th17 cell differentiation and IL-17 production. These results demonstrate that aptamer-facilitated cell specific delivery of shRNA represents a novel approach for efficient RNAi delivery and is potentially to be developed for therapeutics targeting specific T cells subtypes. Published by Elsevier Inc.

Entities:  

Keywords:  Aptamer–shRNA; RORγt; Th17

Mesh:

Substances:

Year:  2014        PMID: 25241192      PMCID: PMC4216182          DOI: 10.1016/j.bbrc.2014.09.037

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

1.  RORC2 is involved in T cell polarization through interaction with the FOXP3 promoter.

Authors:  Simone Burgler; Pierre-Yves Mantel; Claudio Bassin; Nadia Ouaked; Cezmi A Akdis; Carsten B Schmidt-Weber
Journal:  J Immunol       Date:  2010-04-28       Impact factor: 5.422

2.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.

Authors:  Lee Adam Wheeler; Radiana Trifonova; Vladimir Vrbanac; Emre Basar; Shannon McKernan; Zhan Xu; Edward Seung; Maud Deruaz; Tim Dudek; Jon Ivar Einarsson; Linda Yang; Todd M Allen; Andrew D Luster; Andrew M Tager; Derek M Dykxhoorn; Judy Lieberman
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

3.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

4.  Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production.

Authors:  J P van Hamburg; P S Asmawidjaja; N Davelaar; A M C Mus; E M Colin; J M W Hazes; R J E M Dolhain; E Lubberts
Journal:  Arthritis Rheum       Date:  2011-01

5.  IL-17/Th17 mediated synovial inflammation is IL-22 independent.

Authors:  Jan Piet van Hamburg; Odilia B J Corneth; Sandra M J Paulissen; Nadine Davelaar; Patrick S Asmawidjaja; Adriana M C Mus; Erik Lubberts
Journal:  Ann Rheum Dis       Date:  2013-01-17       Impact factor: 19.103

6.  Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis.

Authors:  Rita Cascão; Rita A Moura; Inês Perpétuo; Helena Canhão; Elsa Vieira-Sousa; Ana F Mourão; Ana M Rodrigues; Joaquim Polido-Pereira; Mário V Queiroz; Henrique S Rosário; Maria M Souto-Carneiro; Luis Graca; João E Fonseca
Journal:  Arthritis Res Ther       Date:  2010-10-20       Impact factor: 5.156

7.  Gene transfection and expression in resting and activated murine CD4 T cell subsets.

Authors:  Wendy Lai; Cheong-Hee Chang; Donna L Farber
Journal:  J Immunol Methods       Date:  2003-11       Impact factor: 2.303

8.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

Review 9.  Current progress on aptamer-targeted oligonucleotide therapeutics.

Authors:  Justin P Dassie; Paloma H Giangrande
Journal:  Ther Deliv       Date:  2013-12

Review 10.  Small molecule inhibitors of RORγt: targeting Th17 cells and other applications.

Authors:  Jun R Huh; Dan R Littman
Journal:  Eur J Immunol       Date:  2012-09       Impact factor: 5.532

View more
  7 in total

Review 1.  Applications of RNA interference in the treatment of arthritis.

Authors:  Muhammad Farooq Rai; Hua Pan; Huimin Yan; Linda J Sandell; Christine T N Pham; Samuel A Wickline
Journal:  Transl Res       Date:  2019-07-10       Impact factor: 7.012

Review 2.  Manipulating the in vivo immune response by targeted gene knockdown.

Authors:  Judy Lieberman
Journal:  Curr Opin Immunol       Date:  2015-07-03       Impact factor: 7.486

Review 3.  Aptamer-based targeted therapy.

Authors:  Guizhi Zhu; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-08-17       Impact factor: 15.470

Review 4.  Aptamer-Drug Conjugates.

Authors:  Guizhi Zhu; Gang Niu; Xiaoyuan Chen
Journal:  Bioconjug Chem       Date:  2015-07-14       Impact factor: 4.774

5.  Silencing RORγt in Human CD4+ T cells with CD30 aptamer-RORγt shRNA Chimera.

Authors:  Xiaofei Shi; Pingfang Song; Shao Tao; Xiaowei Zhang; Cong-Qiu Chu
Journal:  Sci Rep       Date:  2019-07-17       Impact factor: 4.379

Review 6.  Targeting Th17 Cells with Small Molecules and Small Interference RNA.

Authors:  Hui Lin; Pingfang Song; Yi Zhao; Li-Jia Xue; Yi Liu; Cong-Qiu Chu
Journal:  Mediators Inflamm       Date:  2015-12-17       Impact factor: 4.711

Review 7.  Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer.

Authors:  Ana Paula Dinis Ano Bom; Patrícia Cristina da Costa Neves; Carlos Eduardo Bonacossa de Almeida; Dilson Silva; Sotiris Missailidis
Journal:  Pharmaceutics       Date:  2019-12-16       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.